Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia:: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis

被引:266
作者
Gleissner, B
Gökbuget, N
Bartram, CR
Janssen, B
Rieder, H
Janssen, JWG
Fonatsch, C
Heyll, A
Voliotis, D
Beck, J
Lipp, T
Munzert, G
Maurer, J
Hoelzer, D
Thiel, E
机构
[1] Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Hematol Oncol & Transfus Med, D-1000 Berlin, Germany
[2] Goethe Univ Frankfurt, Dept Hematol Internal Med, D-6000 Frankfurt, Germany
[3] Heidelberg Univ, Inst Human Genet, D-6900 Heidelberg, Germany
[4] Univ Marburg, Dept Clin Genet, Marburg, Germany
[5] Univ Vienna, Inst Med Biol, A-1010 Vienna, Austria
[6] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-4000 Dusseldorf, Germany
[7] Univ Cologne, Dept Hematol, D-5000 Cologne 41, Germany
[8] Johannes Gutenberg Univ Mainz, Dept Hematol, D-6500 Mainz, Germany
[9] Univ Ulm, Med Dept 3, D-89069 Ulm, Germany
[10] Hosp Munchen Schwabing, Med Dept 1, Munich, Germany
关键词
D O I
10.1182/blood.V99.5.1536
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The BCR-ABL fusion, the molecular equivalent of the Philadelphia translocation, gains Importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this prospective study, samples from 478 patients with CD10(+) B-cell precursor ALL (c-ALL and pre-B ALL) underwent BCR-ABL reverse transcription-polymerase chain reaction (RT-PCR) analysis with double testing of positive samples. Patients were stratified according to the PCR result and treated in 2 German Multicenter Trials of Adult ALL. The outcome was followed and the prognostic impact of BCR-ABL was compared to clinical risk features. of the 478 samples, 432 had an evaluable BCR-ABL result. Thirty-seven percent of the c-ALL and pre-B ALL patients were BCR-ABL(+) (p190, 77%; p210, 20%; simultaneous p190/p210, 3%). BCR-ABL positivity was associated with the high-risk features of older age (45 years versus 30 years median age; P =.0001) and higher white blood cell counts (23 500/muL versus 11 550/muL; P =.0001). Univariate and multivariate analyses revealed BCR-ABL as the leading factor for a poor prognosis (P =.0001) in comparison to clinical risk criteria. Irrespective of the breakpoint, presence of any BCR-ABL transcript predicted a lower chance of initial treatment response (68.4% versus 84.6%; P =.001) and a lower probability of disease-free survival at 3 years (0.13 versus 0.47; P =.0001). This bad outcome was not influenced by postinduction high-dose treatment stratifications. The results show a high prevalence of BCR-ABL fusion transcripts with predominance of p190. BCR-ABL RT-PCR is confirmed as a sensitive, rapid method to diagnose t(9;22), and p190 and p210 are unequivocally demonstrated as the most important predictors of poor long-term survival despite intensified chemotherapy. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:1536 / 1543
页数:8
相关论文
共 44 条
[1]
TRANSLOCATION OF C-ABL ONCOGENE CORRELATES WITH THE PRESENCE OF A PHILADELPHIA-CHROMOSOME IN CHRONIC MYELOCYTIC-LEUKEMIA [J].
BARTRAM, CR ;
DEKLEIN, A ;
HAGEMEIJER, A ;
VANAGTHOVEN, T ;
VANKESSEL, AG ;
BOOTSMA, D ;
GROSVELD, G ;
FERGUSONSMITH, MA ;
DAVIES, T ;
STONE, M ;
HEISTERKAMP, N ;
STEPHENSON, JR ;
GROFFEN, J .
NATURE, 1983, 306 (5940) :277-280
[2]
BEDU A, 1999, BLOOD, V83, P2038
[3]
THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].
BEN-NERIAH, Y ;
DALEY, GQ ;
MESMASSON, AM ;
WITTE, ON ;
BALTIMORE, D .
SCIENCE, 1986, 233 (4760) :212-214
[4]
PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[5]
BLOOMFIELD CD, 1986, BLOOD, V67, P415
[6]
A NOVEL ABL PROTEIN EXPRESSED IN PHILADELPHIA-CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
CHAN, LC ;
KARHI, KK ;
RAYTER, SI ;
HEISTERKAMP, N ;
ERIDANI, S ;
POWLES, R ;
LAWLER, SD ;
GROFFEN, J ;
FOULKES, JG ;
GREAVES, MF ;
WIEDEMANN, LM .
NATURE, 1987, 325 (6105) :635-637
[7]
COX DR, 1972, J R STAT SOC B, V34, P187
[8]
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia [J].
Dekker, AW ;
vantVeer, MB ;
Sizoo, W ;
Haak, HL ;
vanderLelie, J ;
Ossenkoppele, G ;
Huijgens, PC ;
Schouten, HC ;
Sonneveld, P ;
Willemze, R ;
Verdonck, LF ;
vanPutten, WLJ ;
Lowenberg, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :476-482
[9]
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[10]
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566